Prostate Cancer Screening

For asymptomatic men aged 55 to 69 years, the USPSTF supports an individual decision about periodic PSA-based screening after discussion of expected benefits and harms. In the evidence considered by the USPSTF, screening programs may avert approximately 1.3 prostate cancer deaths per 1,000 men over approximately 13 years. JAMAJAMAUSPSTF Recommendation: Screening for Prostate Cancer

Do not frame PSA as a stand-alone cancer test. The screening decision commits the patient to possible repeat testing, imaging, biopsy, diagnosis of indolent disease, surveillance, and potentially treatment-related urinary and sexual adverse effects. Screening should therefore reflect the patient's values regarding avoidance of prostate cancer death versus avoidance of unnecessary testing and diagnosis. BMJ+2BMJProstate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guidelineBMJProstate cancer ‘test by request’ drives overdiagnosis, argue expertsPubMed[Table, MAIN RECOMMENDATIONS OF THE INCLUDED GUIDELINES]. - Prostate Cancer Screening: A Review of the Guidelines - NCBI Bookshelf

Use overall health and estimated life expectancy rather than age alone. A 10-year life-expectancy threshold is commonly used when considering whether local treatment could offer benefit, and guideline summaries advise against screening asymptomatic patients with less than 10-year life expectancy. uroweb+1urowebTreatment - EAU Guidelines on Prostate CancerPubMed[Table, MAIN RECOMMENDATIONS OF THE INCLUDED GUIDELINES]. - Prostate Cancer Screening: A Review of the Guidelines - NCBI Bookshelf

Evidence for PSA screening is mixed. A BMJ guideline concluded that, in lower-risk-of-bias ERSPC trial data over 10 years, PSA screening probably had little or no effect on all-cause mortality and produced approximately 1 fewer prostate cancer death per 1,000 men; longer follow-up estimates suggested 1 to 2 fewer prostate cancer deaths per 1,000 men through 18 years. BMJBMJProstate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline

The Gothenburg component of ERSPC reported a larger apparent effect: after 14 years, prostate cancer mortality declined from 0.9% to 0.5%, an absolute reduction of 0.4%, although PSA testing in the control group was common. BMJBMJScreening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps | BMJ Oncology Differences among trials in screening interval, PSA threshold, adherence, biopsy protocols, and control-arm testing limit direct translation of one trial's effect size to contemporary U.S. practice. BMJBMJProstate cancer screening with prostate-specific antigen ( ...

The central harm is not simply a false-positive PSA; it is the cascade of biopsy, incidental cancer diagnosis, surveillance burden, and treatment of tumors that would not otherwise have caused symptoms or death. PSA screening probably increases localized cancer diagnoses while only modestly reducing advanced disease detection. BMJ+1BMJProstate cancer screening with prostate-specific antigen ( ...BMJProstate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline

PSA and digital rectal examination are key early-detection tools, but cancer diagnosis is confirmed by prostate biopsy. BMJBMJProstate cancer - Symptoms, diagnosis and treatment A raised PSA should prompt clinical reassessment and further evaluation rather than an automatic conclusion that cancer is present. BMJ+1BMJRoutine screening for prostate cancerWHOPolicy statement and recommended actions for early ...

Historical screening trials commonly used PSA thresholds of 3 or 4 ng/mL to trigger systematic biopsy. BMJBMJScreening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps | BMJ Oncology These thresholds are not interchangeable with an individualized contemporary pathway: PSA interpretation should be integrated with age, prostate volume, clinical examination, prior testing, and estimated probability of clinically significant cancer. uroweb+1urowebIntroduction - EAU Guidelines on Prostate CancerWHOSerum PSA-based early detection of prostate cancer in Europe and globally: past, present and future – IARC

A risk-adapted approach using PSA together with age, prostate volume, validated risk calculators, MRI, and targeted biopsy for significant MRI lesions is proposed to improve risk stratification and reduce unnecessary diagnostic procedures and overdiagnosis. uroweb+1urowebIntroduction - EAU Guidelines on Prostate CancerWHOSerum PSA-based early detection of prostate cancer in Europe and globally: past, present and future – IARC The supplied sources do not provide a U.S.-specific PSA retesting interval, MRI threshold, biomarker cutoff, or biopsy protocol; follow current local and specialty guidance for those operational details.

State the expected benefit plainly: PSA screening may slightly reduce prostate cancer mortality over a long time horizon, but it does not clearly reduce all-cause mortality. JAMA+1JAMAUSPSTF Recommendation: Screening for Prostate CancerBMJProstate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline Then describe the tradeoff: screening detects more cancers, especially localized cancers, and a substantial proportion of biopsy evaluations prompted by elevated PSA do not yield cancer. BMJ+1BMJProstate cancer screening with prostate-specific antigen ( ...BMJProstate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline

Elicit what matters most to the patient: reducing the chance of death from prostate cancer, avoiding biopsy and medicalization, preserving quality of life, tolerance for uncertainty, and willingness to undergo follow-up testing. The screening decision should be revisited as health status, life expectancy, and preferences change. JAMA+2JAMAUSPSTF Recommendation: Screening for Prostate CancerurowebTreatment - EAU Guidelines on Prostate CancerPubMed[Table, MAIN RECOMMENDATIONS OF THE INCLUDED GUIDELINES]. - Prostate Cancer Screening: A Review of the Guidelines - NCBI Bookshelf